MARKET

CLVS

CLVS

Clovis Oncology
NASDAQ

Real-time Quotes | Nasdaq Last Sale

5.98
-0.12
-1.97%
After Hours: 6.01 +0.03 +0.50% 19:56 04/16 EDT
OPEN
6.06
PREV CLOSE
6.10
HIGH
6.13
LOW
5.90
VOLUME
3.31M
TURNOVER
--
52 WEEK HIGH
11.10
52 WEEK LOW
4.080
MARKET CAP
625.09M
P/E (TTM)
-1.3448
1D
5D
1M
3M
1Y
5Y
Clovis Oncology Stock Is Believed To Be Possible Value Trap
GuruFocus News · 16h ago
Ovarian Cancer Drugs Market Research Report by Offering, by Technology, by Implementation Methods, by Vertical, by Applications – Global Forecast to 2025 – Cumulative Impact of COVID-19
Heraldkeepers · 4d ago
Clovis Oncology Saturday Morning Highlighted Data On Rubraca Was Presented At American Association For Cancer Research Virtual Annual Meeting
Clovis Oncology, Inc. (NASDAQ:CLVS) announced that Phase 1 clinical data from studies exploring Rubraca in combination with Xtandi for the treatment of advanced prostate cancer (RAMP) and Rubraca monotherapy in advanced
Benzinga · 6d ago
DNA Repair Drugs Market Size is set to Grow at a Remarkable Pace in the Coming Years
Apr 12, 2021 (Market Insight Reports) -- Global DNA Repair Drugs Market DNA repair drugs are widely utilized for repairing damaged DNA, as well as for...
Market Insight Reports · 6d ago
Clovis Oncology's Rubraca shows promise for prostate cancer in phase 1 trial
Phase 1b data presented at the AACR 2021 conference on Clovis Oncology's (CLVS) Rubraca (rucaparib) showed that a combination of the drug with Astellas/Pfizer's Xtandi (enzalutamide) in advanced prostate cancer
Seekingalpha · 04/11 14:00
Clovis Oncology Highlights Rubraca(R) (rucaparib) Clinical Data at AACR Virtual Annual Meeting 2021
Clovis Oncology, Inc. (NASDAQ: CLVS) announced that Phase 1 clinical data from studies exploring Rubraca in combination with Xtandi for the treatment of advanced prostate cancer (RAMP) and Rubraca monotherapy in advanced solid tumors in Japanese patients (...
BusinessWire · 04/10 12:30
Non-Metastatic Castration Resistant Prostate Cancer (nmCRPC) Treatment Market to Grow with a Moderate CAGR During 2021-2029
Apr 09, 2021 (AmericaNewsHour) -- Research Nester released a report titled "Non-Metastatic Castration Resistant Prostate Cancer Treatment Market: Global...
AmericaNewsHour · 04/09 11:23
Poly Polymerase 2 Market Research Report by Type, by Product, by Application - Global Forecast to 2027 - Cumulative Impact of COVID-19
Apr 08, 2021 (Market Stats News via COMTEX) -- The latest report as Poly Polymerase 2 Market acknowledges Size, Application Segment, Type, Regional Outlook,...
Market Stats News · 04/08 18:41
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of CLVS. Analyze the recent business situations of Clovis Oncology through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 6 analysts

Hold

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average CLVS stock price target is 7.13 with a high estimate of 13.00 and a low estimate of 3.000.
EPS
Institutional Holdings
Institutions: 279
Institutional Holdings: 63.19M
% Owned: 60.45%
Shares Outstanding: 104.53M
TypeInstitutionsShares
Increased
50
8.40M
New
26
2.26M
Decreased
44
4.48M
Sold Out
35
2.24M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+0.60%
Pharmaceuticals & Medical Research
+0.89%
Key Executives
Chairman/Independent Director
Ginger Graham
President/Chief Executive Officer/Co-Founder/Director
Patrick Mahaffy
Co-Founder/Executive Vice President
Gillian Ivers-Read
Chief Financial Officer/Executive Vice President
Daniel Muehl
Executive Vice President/General Counsel
Paul Gross
Senior Vice President
C. Dale Hooks
Executive Vice President/Director of Human Resources
Ann Bozeman
Executive Vice President
Lindsey Rolfe
Independent Director
Brian Atwood
Independent Director
Robert Azelby
Independent Director
James Blair
Independent Director
Richard Fair
Independent Director
Keith Flaherty
Independent Director
Paul Klingenstein
Independent Director
Edward McKinley
Independent Director
Thorlef Spickschen
No Data
About CLVS
Clovis Oncology, Inc. is a biopharmaceutical company focused on acquiring, developing and commercializing anti-cancer agents in the United States, Europe and other international markets. The Company’s product Rubraca (rucaparib), an oral small molecule inhibitor of poly adenosine diphosphate (ADP)-ribose polymerase (PARP), is marketed in the United States for two indications specific to recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer. The Company also provides Lucitanib, which is an investigational, oral, potent inhibitor of the tyrosine kinase activity of vascular endothelial growth factor receptors one through three (VEGFR1-3), platelet-derived growth factor receptors alpha and beta, and fibroblast growth factor receptors one through three (FGFR1-3).

Webull offers kinds of Clovis Oncology Inc stock information, including NASDAQ:CLVS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CLVS stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading CLVS stock methods without spending real money on the virtual paper trading platform.